Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

Since April 2011, he has also been the Chairman of Genzyme. In 2011, net sales reached €33,389 million, +3.2% on a reported basis, +5.3% at constant exchange rates (CER) versus 2010. Sanofi has ...

In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for ...

5:00 am EST | Mass General Brigham’s Gene and Cell Therapy Institute is partnering with Cambridge biotech Cellino to create the first in… 3:09 pm EST | A majority of voters here approve of the ...

After hours: February 21 at 7:05:16 PM EST Loading Chart for IGMS ...